Mary Beckerle Sells 9,812 Shares of Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Mary Beckerle sold 9,812 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $53.66, for a total transaction of $526,511.92. Following the completion of the transaction, the director directly owned 16,079 shares of the company’s stock, valued at approximately $862,799.14. The trade was a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Exelixis Stock Performance

Shares of EXEL opened at $50.61 on Friday. The firm’s 50-day simple moving average is $54.21 and its two-hundred day simple moving average is $48.17. Exelixis, Inc. has a fifty-two week low of $33.76 and a fifty-two week high of $57.57. The stock has a market cap of $12.54 billion, a PE ratio of 15.92, a price-to-earnings-growth ratio of 1.50 and a beta of 0.44.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The company had revenue of $628.69 million during the quarter, compared to analyst estimates of $636.40 million. During the same quarter last year, the company earned $0.75 EPS. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. Equities research analysts predict that Exelixis, Inc. will post 3.18 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Citigroup restated a “market outperform” rating on shares of Exelixis in a report on Wednesday, July 22nd. Royal Bank Of Canada raised their price target on Exelixis from $43.00 to $46.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Morgan Stanley lifted their price objective on shares of Exelixis from $50.00 to $53.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $56.00 price target on shares of Exelixis in a research note on Thursday, July 2nd. Finally, UBS Group set a $55.00 price target on shares of Exelixis in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Exelixis currently has a consensus rating of “Hold” and an average target price of $49.79.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Exelixis by 0.5% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 59,420 shares of the biotechnology company’s stock valued at $2,549,000 after purchasing an additional 281 shares during the last quarter. Meeder Advisory Services Inc. increased its holdings in Exelixis by 5.8% in the fourth quarter. Meeder Advisory Services Inc. now owns 5,406 shares of the biotechnology company’s stock valued at $237,000 after buying an additional 298 shares during the last quarter. Cim LLC raised its position in shares of Exelixis by 0.9% during the 3rd quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock worth $1,462,000 after acquiring an additional 305 shares in the last quarter. J.W. Cole Advisors Inc. raised its holdings in Exelixis by 6.5% during the fourth quarter. J.W. Cole Advisors Inc. now owns 5,354 shares of the biotechnology company’s stock worth $235,000 after purchasing an additional 329 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC raised its stake in Exelixis by 3.8% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 9,077 shares of the biotechnology company’s stock worth $389,000 after acquiring an additional 333 shares in the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.